ArticleMedicine2025
Overexpression of the circadian gene Bmal1 regulates the Nrf2/HO-1 oxidative stress pathway to alleviate inflammation and apoptosis in PC12 cells following cerebral ischemia-reperfusion injury.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pathological mechanisms and therapeutic potential of MSC-Exos in ischemic stroke management.Stem cell research & therapy · 2026Review
- Review
- Dynamic Oxidative States: Interplay of Aging, Metabolic Stress, and Circadian Rhythms in Modulating Stroke Severity.Antioxidants (Basel, Switzerland) · 2025Review
- Oxidative Stress-Mediated DNA Damage Induced by Ionizing Radiation in Modern Computed Tomography: Evidence for Antioxidant-Based Radioprotective Strategies.Antioxidants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The circadian clock gene brain and muscle Arnt-like 1 (Bmal1) plays a crucial role in cerebral ischemia-reperfusion injury. Therefore, we established stable transfections of Rat adrenal pheochromocytoma cells (PC12) to overexpress the Bmal1 gene and a negative control using lentivirus. An in vitro model of cerebral ischemia-reperfusion injury was created through oxygen-glucose deprivation/reoxygenation (OGD/R) induction. The cells were divided into 4 groups: control, OGD/R, OGD/R with Bmal1 negative expression, and OGD/R with Bmal1 overexpression. The mRNA expression level of Bmal1 was measured using quantitative reverse transcription polymerase chain reaction. Protein levels of Bmal1, Nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), BCL2-Associated X, B-cell lymphoma-2 (Bcl-2), and cysteine-dependent aspartate-directed protease 3 were assessed via Western blotting. The levels of inflammatory cytokines interleukin-6, and interleukin-1β in the cell supernatant were quantified using ELISA. Apoptosis rates were analyzed by flow cytometry, and intracellular reactive oxygen species levels were measured using a fluorescent probe. Following OGD/R induction, Bmal1 gene and protein expression levels were reduced in PC12 cells. After lentiviral transfection, mRNA and protein expression levels of Bmal1 significantly increased in the overexpression model. Bmal1 overexpression down-regulated apoptotic proteins BCL2-Associated X and cysteine-dependent aspartate-directed protease 3, up-regulated the antiapoptotic protein Bcl-2, reduced apoptosis, and inhibited the release of inflammatory factors interleukin-6 and interleukin-1β following OGD/R. Further experiments indicated that Bmal1 overexpression activated proteins in the Nrf2/HO-1 oxidative stress signaling pathway, reducing intracellular reactive oxygen species release. This study demonstrated that Bmal1 overexpression inhibits inflammatory responses and apoptosis in PC12 cells after ischemia/reperfusion injury by regulating the Nrf2/HO-1 oxidative stress signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.